FWBI

First Wave BioPharma, Inc. [FWBI] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

FWBI Stock Summary

Top 10 Correlated Stocks

FWBI


In the News

08:45 26 Sep 2023 FWBI

First Wave BioPharma To Present at the BIO Investor Forum

BOCA RATON, Fla., Sept. 15, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, President and CEO, will make a company presentation at the BIO Investor Forum being held October 17-18, 2023, at the Hilton San Francisco Union Square in San Francisco.

07:07 26 Sep 2023 FWBI

First Wave BioPharma stock soars in active trading after Sanofi license deal

Shares of First Wave BioPharma Inc. FWBI, +8.61% soared 71.7% in active premarket trading Thursday, after the biopharmaceutical company announced an agreement to license Capeserod to Sanofi SNY, -0.73%, which First Wave will repurpose and develop for gastrointestinal indications. Trading volume swelled to 6.5 million shares, already more than double the full-day average of about 2.6 million shares, and enough to make the stock the third-most actively traded in Thursday's premarket.

11:54 26 Sep 2023 FWBI

First Wave (FWBI) Down 32% on Cystic Fibrosis Study Setback

Initial data from First Wave's (FWBI) mid-stage study evaluating its investigational oral capsule in cystic fibrosis patients did not likely meet its primary endpoint.

11:27 26 Sep 2023 FWBI

First Wave (FWBI) Surges 33% on Finishing Enrolment in CF Study

First Wave (FWBI) completes enrolment in a mid-stage study evaluating its investigational oral capsule in patients with cystic fibrosis. Topline data from the study is expected next month.

07:00 26 Sep 2023 FWBI

First Wave BioPharma CEO James Sapirstein to Present at 2023 BIO International Conference

BOCA RATON, Fla., May 15, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that James Sapirstein, Chief Executive Officer of First Wave BioPharma, will present at the 2023 BIO International Conference on Tuesday, June 6 11:45 AM in Room 104A. The conference is taking place June 5-8 in the Boston Convention & Exhibition Center in Boston, Massachusetts.

07:00 26 Sep 2023 FWBI

First Wave BioPharma to Present at the BIO CEO & Investor Conference

BOCA RATON, Fla., Jan. 30, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced James Sapirstein, Chairman, President and CEO, will present at the BIO CEO & Investor Conference being held February 6-9, 2023, at the Marriott Marquis in New York City.

11:36 26 Sep 2023 FWBI

Why Is First Wave BioPharma (FWBI) Stock Up 30% Today?

Many Nasdaq stocks were in the red this morning, but not First Wave BioPharma (NASDAQ: FWBI ) stock. Indeed, First Wave shares were up substantially after the company announced an addition to its intellectual property (IP) portfolio governing a proprietary drug called adrulipase.

07:00 26 Sep 2023 FWBI

First Wave BioPharma to Present at Sequire Biotechnology Conference

BOCA RATON, Fla., Jan. 24, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced James Sapirstein, Chairman, President and CEO, will present at the Sequire Biotechnology Conference being held virtually on February 2, 2023.

02:18 26 Sep 2023 FWBI

First Wave (FWBI) IND Filing Under FDA's Review, Stock Up

First Wave's (FWBI) stock gains as FDA reviews its IND amendment for the planned phase II study of an enhanced enteric microgranule delivery formulation of adrulipase.

07:00 26 Sep 2023 FWBI

First Wave BioPharma's CEO James Sapirstein to Present at Inaugural Roth Healthcare Opportunities Conference

BOCA RATON, Fla., Sept. 28, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman, President, and CEO of First Wave BioPharma, will give a presentation and take investor meetings at the Inaugural Roth Healthcare Opportunities Conference taking place October 6, 2022, in New York City.

FWBI Financial details

Company Rating
Neutral
Market Cap
2.49M
Income
-9.58M
Revenue
0
Book val./share
0.39
Cash/share
0.54
Dividend
-
Dividend %
-
Employees
10
Optionable
No
Shortable
Yes
Earnings
14 Nov 2023
P/E
-0.08
Forward P/E
-
PEG
0.01
P/S
-
P/B
0.9
P/C
0.6
P/FCF
-0.16
Quick Ratio
0.38
Current Ratio
0.72
Debt / Equity
0.46
LT Debt / Equity
0.21
-
-
EPS (TTM)
-3.84
EPS next Y
-
EPS next Q
-
EPS this Y
-98.34%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-85.34%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0.15%
Inst Trans
0%
ROA
-221%
ROE
-944%
ROC
-5.75%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-1%
Shs Outstand
7.15M
Shs Float
7.12M
-
-
-
-
Target Price
270
52W Range
0.273-16.38
52W High
-
52W Low
-
RSI
39
Rel Volume
0.17
Avg Volume
3.66M
Volume
605.68K
Perf Week
-26.14%
Perf Month
-22.99%
Perf Quarter
-87.92%
Perf Half Y
-89.27%
-
-
-
-
Beta
1.61826
-
-
Volatility
0.02%, 0.05%
Prev Close
-6.82%
Price
0.325
Change
-7.14%

FWBI Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
Revenue per share
00000
Net income per share
-1.84K-1.46K-2.86K-1.39K-23.09
Operating cash flow per share
-1.48K-1.31K-828.71-759.67-31.11
Free cash flow per share
-1.49K-1.32K-829.02-1K-31.11
Cash per share
151.5716.46447.69194.071.9
Book value per share
608.52432.41-195.01-184.023.82
Tangible book value per share
269.12-63.36-559.36-2291.47
Share holders equity per share
608.52432.41-195.01-184.023.82
Interest debt per share
48.54190.9477.7824.511.25
Market cap
18.68M23.32M27.58M12.9M4.4M
Enterprise value
17.82M24.75M22.15M5.68M3.92M
P/E ratio
-1.38-1.49-0.71-0.22-0.27
Price to sales ratio
00000
POCF ratio
-1.72-1.66-2.46-0.4-0.2
PFCF ratio
-1.71-1.66-2.46-0.3-0.2
P/B Ratio
4.185.05-10.45-1.651.61
PTB ratio
4.185.05-10.45-1.651.61
EV to sales
00000
Enterprise value over EBITDA
-1.41-1.8-0.86-0.1-0.3
EV to operating cash flow
-1.64-1.76-1.97-0.18-0.18
EV to free cash flow
-1.63-1.76-1.97-0.13-0.18
Earnings yield
-0.72-0.67-1.4-4.58-3.77
Free cash flow yield
-0.58-0.6-0.41-3.3-5.07
Debt to equity
0.060.35-0.24-0.130.32
Debt to assets
0.030.180.050.090.16
Net debt to EBITDA
0.07-0.10.210.130.04
Current ratio
1.60.80.510.771.37
Interest coverage
-131.88-33.98-4.53-5.26K-798.42
Income quality
0.80.920.340.551.53
Dividend Yield
00.070.3349.46K0.01
Payout ratio
0-0.11-0.21-76.29K0
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
0.330.590.380.160.31
Capex to operating cash flow
0.01000.320
Capex to revenue
00000
Capex to depreciation
-0.07-0.02-0.01-19.030
Stock based compensation to revenue
00000
Graham number
5.02K3.77K3.54K2.4K44.53
ROIC
-2.82-2.4116.199.31-3.68
Return on tangible assets
-2.72-4.33-4.85-5.98-4.42
Graham Net
67.78-199.65-671.21-267.34-1.76
Working capital
1.8M-877.35K-7.68M-2.88M929.27K
Tangible asset value
1.98M-676.53K-7.57M-9.73M1.06M
Net current asset value
1.8M-877.35K-7.69M-10.19M715.21K
Invested capital
0.060.35-0.24-0.130.32
Average receivables
2.14M2.9M1.59M275.74K46.51K
Average payables
1.45M2.21M1.89M2.12M1.7M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-3.03-3.3814.667.55-6.05
Capex per share
-7.55-2.26-0.31-242.790

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric History 2022-06-302022-09-302022-12-312023-03-31 2023-06-30
Revenue per share
00000
Net income per share
-52.119.2-7.93-12.55-1.84
Operating cash flow per share
-44.16-18.6-7.79-8.73-1.22
Free cash flow per share
-44.16-18.6-7.79-8.73-1.22
Cash per share
11.127.241.96.340.54
Book value per share
-136.65-9.973.828.330.39
Tangible book value per share
-153.55-17.461.473.16-0.35
Share holders equity per share
-136.65-9.973.828.330.39
Interest debt per share
4.581.31.242.010.18
Market cap
4.36M2.37M4.4M873.17K3.63M
Enterprise value
3.68M1.01M3.92M-546.41K2.8M
P/E ratio
-0.20.13-0.19-0.05-0.22
Price to sales ratio
00000
POCF ratio
-0.95-0.56-0.79-0.31-1.32
PFCF ratio
-0.95-0.56-0.79-0.31-1.32
P/B Ratio
-0.31-1.041.610.324.12
PTB ratio
-0.31-1.041.610.324.12
EV to sales
00000
Enterprise value over EBITDA
-0.680.23-0.990.13-0.67
EV to operating cash flow
-0.8-0.24-0.70.19-1.01
EV to free cash flow
-0.8-0.24-0.70.19-1.01
Earnings yield
-1.241.85-1.29-4.68-1.15
Free cash flow yield
-1.05-1.79-1.27-3.26-0.76
Debt to equity
-0.03-0.130.320.240.46
Debt to assets
0.120.060.160.120.09
Net debt to EBITDA
0.13-0.310.120.350.2
Current ratio
0.10.381.371.340.72
Interest coverage
-1.68K5.09K-368.1-452.03-807.58
Income quality
0.85-0.971.40.70.66
Dividend Yield
000.010.10
Payout ratio
00-0.01-0.020
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
0.450.370.310.30.39
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
00000
Graham number
400.2465.6126.0948.484.01
ROIC
0.4-2.6-0.83-1.13-2.73
Return on tangible assets
-2.491.5-1.52-1.06-1.58
Graham Net
-162.83-22.4-1.76-2.28-0.97
Working capital
-15.49M-4.15M929.27K905.02K-907.46K
Tangible asset value
-15.95M-3.99M1.06M1.03M-802.22K
Net current asset value
-16.33M-4.38M715.21K708.49K-1.09M
Invested capital
-0.03-0.130.320.240.46
Average receivables
49.24K131.21K142.5K56.51K10K
Average payables
3.71M3.77M2.15M594.9K1.03M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
0.38-1.93-2.08-1.51-4.75
Capex per share
00000

FWBI Frequently Asked Questions

What is First Wave BioPharma, Inc. stock symbol ?

First Wave BioPharma, Inc. is a US stock , located in Boca raton of Fl and trading under the symbol FWBI

What is First Wave BioPharma, Inc. stock quote today ?

First Wave BioPharma, Inc. stock price is $0.325 today.

Is First Wave BioPharma, Inc. stock public?

Yes, First Wave BioPharma, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Top Correlated Stocks
Similar Market Cap